Angulo Gonzalez David
Known title: Chief Medical OfficerCIK: 0001644071
Angulo Gonzalez David's purchase track record
Angulo Gonzalez David has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/12/2024 | SCYX | $27K | -17.2% | -36.0% | -1.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| SCYX | ▲ Buy | Open Market | 108,695 | — | 4/1/2026 | View on chart |
| SCYX | ▲ Buy | Grant | 391,333 | $0 | 1/29/2026 | View on chart |
| SCYX | ▲ Buy | Grant | 32,500 | $25K | 10/17/2025 | View on chart |
| SCYX | ▲ Buy | Grant | 23,000 | $19K | 4/9/2025 | View on chart |
| SCYX | ▲ Buy | Grant | 13,800 | $14K | 3/20/2025 | View on chart |
| SCYX | ▲ Buy | Grant | 5,000 | $5K | 3/19/2025 | View on chart |
| SCYX | ▲ Buy | Grant | 262,927 | $0 | 1/23/2025 | View on chart |
| SCYX | ▲ Buy | Open Market | 20,000 | $27K | 9/12/2024 | View on chart |
| SCYX | ▲ Buy | Grant | 290,590 | $0 | 1/26/2024 | View on chart |
| SCYX | ▲ Buy | Grant | 110,000 | $0 | 1/1/2023 | View on chart |
| SCYX | ▲ Buy | Grant | 51,100 | $0 | 2/4/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
SCYNEXIS Wins $214M BARDA Contract for SCY-247
SCYNEXIS received a contract from the U.S. Department of Defense's BARDA agency worth up to $214 million. This non-dilutive funding supports the development of the company's SCY-247 drug. The news drove the stock price up by nearly 14% on Tuesday, marking a significant positive event for the company.
SCYNEXIS Wins $214M BARDA Contract for SCY-247. SCYNEXIS received a contract from the U.S. Department of Defense's BARDA agency worth up to $214 million. This non-dilutive funding supports the development of the company's SCY-247 drug. The news drove the stock price up by nearly 14% on Tuesday, marking a significant positive event for the company.